Search

You searched for "Glasgow"

74 results found

Prostate cancer

1 July 2015 | | URO - Urologic Oncology
Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...

Men with a susceptibility to prostate cancer: implications of ethnicity in PCa risk-prediction and diagnosis

5 January 2022 | | URO - Urologic Oncology
The diagnostic and therapeutic landscapes of prostate cancer (PCa) have advanced at great pace in the past decade. However, disparities in access to care, clinical outcomes and representation in therapeutic, interventional and genomic studies continue to exist between Afro-Caribbean (AC)...

MRI screening for prostate cancer: a step towards a ‘prostagram’

7 January 2020 | | URO - Urologic Oncology, URO - Technology
The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...

Robotic assisted perineal prostatectomy: descriptive technique of the inaugural case in the UK

1 January 2019 | | URO - Urologic Oncology, URO - Technology
Robotic surgery has taken full flight in the USA since its start in 2000 [1] and is replacing procedures where open surgical techniques were solely employed. While this technology is met with criticism over the costs, the superiority of robotic...

Demanding cases or nightmares in uro-oncology? Jan/Feb 2023

6 January 2023 | | URO - Urologic Oncology
Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...

Ejaculatory dysfunction: a review of current practice and guidelines

1 January 2015 | | URO - Andrology
Introduction The ejaculatory process is paramount to procreation in nature. It is a complex orchestration of physiology that results in emission of the ejaculate into the posterior urethra followed by ejection of those fluids from the urethra and orgasm. The...

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

3 March 2021 | | URO - Urologic Oncology, URO - Technology
The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...

Improving on the Rotterdam Prostate Cancer Risk Calculator

1 January 2019 | | URO - Technology
Following the PROMIS trial [1], many cancer centres in the UK are now offering pre-biopsy multiparametric MRI (mpMRI) for men suitable for radical treatment. The European Association of Urology for Prostate Cancer (PCa) guidelines recommend individual risk stratification before the...

PREDICT Prostate – individualised, evidence-based estimates of survival and treatment benefit

5 November 2019 | | URO - Urologic Oncology, URO - Technology
Earlier this year ‘PREDICT Prostate’ was launched online alongside a high-profile publication in PLOS Medicine. The prognostic model and decision-aid has been designed to inform treatment decision-making among men newly diagnosed with non-metastatic prostate cancer. David Thurtle and Vincent Gnanapragasam...

Rotterdam Prostate Cancer Risk app

1 July 2014 | | URO - Urologic Oncology, URO - Technology
The widespread use of prostate specific antigen (PSA) testing has led to diagnostic difficulties for patients and urologists. The sensitivity and specificity characteristics of PSA are far from optimal. To try and improve the predictive accuracy of PSA measurements, nomograms...

Prostate cancer

8 November 2021 | | URO - Urologic Oncology
Case 1 A 65-year-old man is referred to your two-week wait (2WW) clinic with a PSA of 7.0ng/mL. He has no lower urinary tract symptoms (LUTS), no past medical history, no family history of prostate cancer (PCa) and his performance...

Establishing a new TPPBx service during the COVID-19 pandemic

6 November 2020 | | URO - Urologic Oncology, URO - Technology
COVID-19 had a major impact on our hospital services from early in the pandemic, with almost three times as many patients being ventilated compared to the normal ITU capacity at the beginning of April. During the build-up to this point,...